The influence of IS 1301 in the capsule biosynthesis locus on meningococcal carriage and disease

PLoS ONE

Volumn 5, Issue 2, 2010, Pages

  Kugelberg, Elisabeth ^a   Gollan, Bridget ^a   Farrance, Christopher ^a   Bratcher, Holly ^b   Lucidarme, Jay ^c   Ibarz Pavón, Ana Belén ^b   Maiden, Martin C J ^b   Borrow, Ray ^c   Tang, Christoph M ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SPACER DNA; VACCINE; BACTERIAL DNA; BACTERIAL PROTEIN; COMPLEMENT; MENINGOCOCCUS VACCINE;

ARTICLE; BACTERIUM ISOLATE; BIOSYNTHESIS; BLOOD GROUP TYPING; GENE INSERTION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENOTYPE; MENINGOCOCCOSIS; MICROCAPSULE; NEISSERIA MENINGITIDIS; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; SPAIN; UNITED KINGDOM; VACCINE FAILURE; BACTERIAL MEMBRANE; CLASSIFICATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; NUCLEOTIDE SEQUENCE; PHYLOGENY; SEQUENCE HOMOLOGY; TRANSPOSON;

NEISSERIA MENINGITIDIS;

BACTERIAL CAPSULES; BACTERIAL PROTEINS; BASE SEQUENCE; COMPLEMENT SYSTEM PROTEINS; DNA TRANSPOSABLE ELEMENTS; DNA, BACTERIAL; DNA, INTERGENIC; GREAT BRITAIN; HUMANS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MUTAGENESIS, INSERTIONAL; NEISSERIA MENINGITIDIS, SEROGROUP B; NEISSERIA MENINGITIDIS, SEROGROUP C; PHYLOGENY; SEQUENCE HOMOLOGY, NUCLEIC ACID; SPAIN;

EID: 77949676658     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0009413     Document Type: Article

References (29)

1. Cartwright KA, Stuart JM, Jones DM, Noah ND (1987) The Stonehouse survey: nasopharyngeal carriage of meningococci and Neisseria lactamica. Epidemiol Infect 99: 591-601.
2. Caugant DA, Hoiby EA, Magnus P, Scheel O, Hoel T, et al. (1994) Asymptomatic carriage of Neisseria meningitidis in a randomly sampled population. J Clin Microbiol 32: 323-330.
3. Kugelberg E, Gollan B, Tang CM (2008) Mechanisms in Neisseria meningitidis for resistance against complement-mediated killing. Vaccine 26: I34-39.
4. Maiden MC, Bygraves JA, Feil E, Morelli G, Russell JE, et al. (1998) Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A 95: 3140-3145.
5. Yazdankhah SP, Caugant DA (2004) Neisseria meningitidis: an overview of the carriage state. J Med Microbiol 53: 821-832.
6. Uria MJ, Zhang Q, Li Y, Chan A, Exley RM, et al. (2008) A generic mechanism in Neisseria meningitidis for enhanced resistance against bactericidal antibodies. J Exp Med 205: 1423-1434.
7. Balmer P, Borrow R, Miller E (2002) Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol 51: 717-722.
8. Miller E, Salisbury D, Ramsay M (2001) Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 20 Suppl 1: S58-67.
9. Ramsay ME, Andrews N, Kaczmarski EB, Miller E (2001) Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 357: 195-196.
10. Trotter CL, Ramsay ME (2007) Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol Rev 31: 101-107.
11. Auckland C, Gray S, Borrow R, Andrews N, Goldblatt D, et al. (2006) Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis 194: 1745-1752.
12. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME (2004) Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364: 365-367.
13. Andrews N, Borrow R, Miller E (2003) Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from post licensure surveillance in England. Clin Diagn Lab Immunol 10: 780-786.
14. Goldschneider I, Gotschlich EC, Artenstein MS (1969) Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 129: 1307-1326.
15. Gray SJ, Trotter CL, Ramsay ME, Guiver M, Fox AJ, et al. (2006) Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit. J Med Microbiol 55: 887-896.
16. Russell JE, Urwin R, Gray SJ, Fox AJ, Feavers IM, et al. (2008) Molecular epidemiology of meningococcal disease in England and Wales 1975-1995, before the introduction of serogroup C conjugate vaccines. Microbiology 154: 1170-1177.
17. Bille E, Ure R, Gray SJ, Kaczmarski EB, McCarthy ND, et al. (2008) Association of a bacteriophage with meningococcal disease in young adults. PLoS One 3: e3885.
18. Maiden MC, Stuart JM (2002) Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 359: 1829-1831.
19. Diggle MA, Clarke SC (2005) Increased genetic diversity of Neisseria meningitidis isolates after the introduction of meningococcal serogroup C polysaccharide conjugate vaccines. J Clin Microbiol 43: 4649-4653.
20. Von Loewenich FD, Wintermeyer E, Dumig M, Frosch M (2001) Analysis of transcriptional control mechanisms of capsule expression in Neisseria meningitidis. Int J Med Microbiol 291: 361-369.
21. Hammerschmidt S, Hilse R, van Putten JP, Gerardy-Schahn R, Unkmeir A, et al. (1996) Modulation of cell surface sialic acid expression in Neisseria meningitidis via a transposable genetic element. Embo J 15: 192-198.
22. Lucidarme J, Comanducci M, Findlow J, Gray S, Kaczmarski E, et al. (2009) Characterisation of fHbp, nhba (gna2132), nadA, porA, Sequence Type and the genomic presence of IS1301 in group B meningococcal ST269 clonal complex case-isolates from England and Wales. J Clin Microbiol 47: 3577-3585.
23. Bille E, Zahar JR, Perrin A, Morelle S, Kriz P, et al. (2005) A chromosomally integrated bacteriophage in invasive meningococci. J Exp Med 201: 1905-1913.
24. Harrison OB, Evans NJ, Blair JM, Grimes HS, Tinsley CR, et al. (2009) Epidemiological evidence for the role of the hemoglobin receptor, hmbR, in meningococcal virulence. J Infect Dis 200: 94-98.
25. Maiden MC, Ibarz-Pavon AB, Urwin R, Gray SJ, Andrews NJ, et al. (2008) Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 197: 737-743.
26. El-Robh MS, Busby SJ (2002) The Escherichia coli cAMP receptor protein bound at a single target can activate transcription initiation at divergent promoters: a systematic study that exploits new promoter probe plasmids. Biochem J 368: 835-843.
27. Miller JH (1972) Experiments in Molecular Genetics. New York: Cold Spring Harbor Laboratory Press.
28. Swartley JS, Ahn JH, Liu LJ, Kahler CM, Stephens DS (1996) Expression of sialic acid and polysialic acid in serogroup B Neisseria meningitidis: divergent transcription of biosynthesis and transport operons through a common promoter region. J Bacteriol 178: 4052-4059.
29. Huson DH, Bryant D (2006) Application of phylogenetic networks in evolutionary studies. Mol Biol Evol 23: 254-267.